



Therapeutic Radioligands Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-28	127	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Therapeutic Radioligands Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Therapeutic Radioligands Drug market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Therapeutic Radioligands Drug market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Therapeutic Radioligands Drug market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Therapeutic Radioligands Drug include Novartis, Mundipharma, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med and Nordic Nanovector, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Therapeutic Radioligands Drug market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Therapeutic Radioligands Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Therapeutic Radioligands Drug Market by Company

Novartis

Mundipharma

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals
RadioMedix
Philogen
Orano Med
Nordic Nanovector
Lantheus
Gilead Sciences
Fusion Pharmaceuticals
Curium Pharmaceuticals
Curasight
Clarity Pharmaceuticals
China Isotope & Radiation
Aurobindo Pharma
Actinium Pharmaceuticals

Therapeutic Radioligands Drug Segment by Type

Beta-emitting
Targeted Alpha Therapy

Therapeutic Radioligands Drug Segment by Application

Solid Tumor
Non Hodgkin Lymphoma

Therapeutic Radioligands Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radioligands Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radioligands Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radioligands Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Therapeutic Radioligands Drug companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Therapeutic Radioligands Drug by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Beta-emitting
 - 2.2.3 Targeted Alpha Therapy
- 2.3 Therapeutic Radioligands Drug by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Solid Tumor
 - 2.3.3 Non Hodgkin Lymphoma
- 2.4 Assumptions and Limitations

3 Therapeutic Radioligands Drug Breakdown Data by Type

- 3.1 Global Therapeutic Radioligands Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Therapeutic Radioligands Drug Forecasted Market Size by Type (2027-2032)

4 Therapeutic Radioligands Drug Breakdown Data by Application

- 4.1 Global Therapeutic Radioligands Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Therapeutic Radioligands Drug Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Therapeutic Radioligands Drug Market Perspective (2021-2032)
- 5.2 Global Therapeutic Radioligands Drug Growth Trends by Region
 - 5.2.1 Global Therapeutic Radioligands Drug Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Therapeutic Radioligands Drug Historic Market Size by Region (2021-2026)
 - 5.2.3 Therapeutic Radioligands Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Therapeutic Radioligands Drug Market Dynamics
 - 5.3.1 Therapeutic Radioligands Drug Industry Trends
 - 5.3.2 Therapeutic Radioligands Drug Market Drivers
 - 5.3.3 Therapeutic Radioligands Drug Market Challenges
 - 5.3.4 Therapeutic Radioligands Drug Market Restraints

6 Market Competitive Landscape by Players

- 6.1 Global Top Therapeutic Radioligands Drug Players by Revenue
 - 6.1.1 Global Top Therapeutic Radioligands Drug Players by Revenue (2021-2026)
 - 6.1.2 Global Therapeutic Radioligands Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Therapeutic Radioligands Drug Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Therapeutic Radioligands Drug Head Office and Area Served

6.4 Global Therapeutic Radioligands Drug Players, Product Type & Application

6.5 Global Therapeutic Radioligands Drug Manufacturers Established Date

6.6 Global Therapeutic Radioligands Drug Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 North America

7.1 North America Therapeutic Radioligands Drug Market Size (2021-2032)

7.2 North America Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Therapeutic Radioligands Drug Market Size by Country (2021-2026)

7.4 North America Therapeutic Radioligands Drug Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

8 Europe

8.1 Europe Therapeutic Radioligands Drug Market Size (2021-2032)

8.2 Europe Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Therapeutic Radioligands Drug Market Size by Country (2021-2026)

8.4 Europe Therapeutic Radioligands Drug Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

9 Asia-Pacific

9.1 Asia-Pacific Therapeutic Radioligands Drug Market Size (2021-2032)

9.2 Asia-Pacific Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Therapeutic Radioligands Drug Market Size by Country (2021-2026)

9.4 Asia-Pacific Therapeutic Radioligands Drug Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

10 South America

10.1 South America Therapeutic Radioligands Drug Market Size (2021-2032)

10.2 South America Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Therapeutic Radioligands Drug Market Size by Country (2021-2026)

10.4 South America Therapeutic Radioligands Drug Market Size by Country (2027-2032)

10.5 Brazil

10.6 Argentina

10.7 Chile

10.8 Colombia

10.9 Peru

11 Middle East & Africa

11.1 Middle East & Africa Therapeutic Radioligands Drug Market Size (2021-2032)

11.2 Middle East & Africa Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032

11.3 Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2021-2026)

11.4 Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2027-2032)

11.5 Saudi Arabia

11.6 Israel

11.7 United Arab Emirates

11.8 Turkey

11.9 Iran

11.10 Egypt

12 Players Profiled

12.1 Novartis

12.1.1 Novartis Company Information

12.1.2 Novartis Business Overview

12.1.3 Novartis Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.1.4 Novartis Therapeutic Radioligands Drug Product Portfolio

12.1.5 Novartis Recent Developments

12.2 Mundipharma

12.2.1 Mundipharma Company Information

12.2.2 Mundipharma Business Overview

12.2.3 Mundipharma Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.2.4 Mundipharma Therapeutic Radioligands Drug Product Portfolio

12.2.5 Mundipharma Recent Developments

12.3 Bayer

12.3.1 Bayer Company Information

12.3.2 Bayer Business Overview

12.3.3 Bayer Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.3.4 Bayer Therapeutic Radioligands Drug Product Portfolio

12.3.5 Bayer Recent Developments

12.4 Y-mAbs Therapeutics

12.4.1 Y-mAbs Therapeutics Company Information

12.4.2 Y-mAbs Therapeutics Business Overview

12.4.3 Y-mAbs Therapeutics Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.4.4 Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio

12.4.5 Y-mAbs Therapeutics Recent Developments

12.5 Telix Pharmaceuticals

12.5.1 Telix Pharmaceuticals Company Information

12.5.2 Telix Pharmaceuticals Business Overview

12.5.3 Telix Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.5.4 Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio

12.5.5 Telix Pharmaceuticals Recent Developments

12.6 RadioMedix

12.6.1 RadioMedix Company Information

12.6.2 RadioMedix Business Overview

12.6.3 RadioMedix Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.6.4 RadioMedix Therapeutic Radioligands Drug Product Portfolio

12.6.5 RadioMedix Recent Developments

12.7 Philogen

12.7.1 Philogen Company Information

12.7.2 Philogen Business Overview

12.7.3 Philogen Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.7.4 Philogen Therapeutic Radioligands Drug Product Portfolio

12.7.5 Philogen Recent Developments

12.8 Orano Med

12.8.1 Orano Med Company Information

12.8.2 Orano Med Business Overview

12.8.3 Orano Med Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.8.4 Orano Med Therapeutic Radioligands Drug Product Portfolio

12.8.5 Orano Med Recent Developments

12.9 Nordic Nanovector

12.9.1 Nordic Nanovector Company Information

12.9.2 Nordic Nanovector Business Overview

12.9.3 Nordic Nanovector Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.9.4 Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio

12.9.5 Nordic Nanovector Recent Developments

12.10 Lantheus

12.10.1 Lantheus Company Information

12.10.2 Lantheus Business Overview

12.10.3 Lantheus Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.10.4 Lantheus Therapeutic Radioligands Drug Product Portfolio

12.10.5 Lantheus Recent Developments

12.11 Gilead Sciences

12.11.1 Gilead Sciences Company Information

12.11.2 Gilead Sciences Business Overview

12.11.3 Gilead Sciences Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.11.4 Gilead Sciences Therapeutic Radioligands Drug Product Portfolio

12.11.5 Gilead Sciences Recent Developments

12.12 Fusion Pharmaceuticals

12.12.1 Fusion Pharmaceuticals Company Information

12.12.2 Fusion Pharmaceuticals Business Overview

12.12.3 Fusion Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.12.4 Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio

12.12.5 Fusion Pharmaceuticals Recent Developments

12.13 Curium Pharmaceuticals

12.13.1 Curium Pharmaceuticals Company Information

12.13.2 Curium Pharmaceuticals Business Overview

12.13.3 Curium Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.13.4 Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio

12.13.5 Curium Pharmaceuticals Recent Developments

12.14 Curasight

12.14.1 Curasight Company Information

12.14.2 Curasight Business Overview

12.14.3 Curasight Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.14.4 Curasight Therapeutic Radioligands Drug Product Portfolio

12.14.5 Curasight Recent Developments

12.15 Clarity Pharmaceuticals

12.15.1 Clarity Pharmaceuticals Company Information

12.15.2 Clarity Pharmaceuticals Business Overview

12.15.3 Clarity Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.15.4 Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio

12.15.5 Clarity Pharmaceuticals Recent Developments

12.16 China Isotope & Radiation

12.16.1 China Isotope & Radiation Company Information

12.16.2 China Isotope & Radiation Business Overview

12.16.3 China Isotope & Radiation Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.16.4 China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio

12.16.5 China Isotope & Radiation Recent Developments

12.17 Aurobindo Pharma

12.17.1 Aurobindo Pharma Company Information

12.17.2 Aurobindo Pharma Business Overview

12.17.3 Aurobindo Pharma Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.17.4 Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio

12.17.5 Aurobindo Pharma Recent Developments

12.18 Actinium Pharmaceuticals

12.18.1 Actinium Pharmaceuticals Company Information

12.18.2 Actinium Pharmaceuticals Business Overview

12.18.3 Actinium Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026)

12.18.4 Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio

12.18.5 Actinium Pharmaceuticals Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Therapeutic Radioligands Drug Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Therapeutic Radioligands Drug Revenue Market Share by Type (2021-2026)
- Table 7: Global Therapeutic Radioligands Drug Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Therapeutic Radioligands Drug Revenue Market Share by Type (2027-2032)
- Table 9: Global Therapeutic Radioligands Drug Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Therapeutic Radioligands Drug Revenue Market Share by Application (2021-2026)
- Table 11: Global Therapeutic Radioligands Drug Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Therapeutic Radioligands Drug Revenue Market Share by Application (2027-2032)
- Table 13: Global Therapeutic Radioligands Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Therapeutic Radioligands Drug Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Therapeutic Radioligands Drug Market Share by Region (2021-2026)
- Table 16: Global Therapeutic Radioligands Drug Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Therapeutic Radioligands Drug Market Share by Region (2027-2032)
- Table 18: Therapeutic Radioligands Drug Industry Trends
- Table 19: Therapeutic Radioligands Drug Industry Drivers
- Table 20: Therapeutic Radioligands Drug Industry Opportunities and Challenges
- Table 21: Therapeutic Radioligands Drug Market Restraints
- Table 22: Global Top Therapeutic Radioligands Drug Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Therapeutic Radioligands Drug Revenue Market Share by Players (2021-2026)
- Table 24: Global Therapeutic Radioligands Drug Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Therapeutic Radioligands Drug, Headquarters and Area Served
- Table 26: Global Therapeutic Radioligands Drug Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Therapeutic Radioligands Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Therapeutic Radioligands Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Therapeutic Radioligands Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Therapeutic Radioligands Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Therapeutic Radioligands Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Therapeutic Radioligands Drug Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Therapeutic Radioligands Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Therapeutic Radioligands Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Therapeutic Radioligands Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Therapeutic Radioligands Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Therapeutic Radioligands Drug Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Novartis Company Information
- Table 46: Novartis Business Overview
- Table 47: Novartis Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 48: Novartis Therapeutic Radioligands Drug Product Portfolio
- Table 49: Novartis Recent Developments
- Table 50: Mundipharma Company Information
- Table 51: Mundipharma Business Overview
- Table 52: Mundipharma Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)

- Table 53: Mundipharma Therapeutic Radioligands Drug Product Portfolio
- Table 54: Mundipharma Recent Developments
- Table 55: Bayer Company Information
- Table 56: Bayer Business Overview
- Table 57: Bayer Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 58: Bayer Therapeutic Radioligands Drug Product Portfolio
- Table 59: Bayer Recent Developments
- Table 60: Y-mAbs Therapeutics Company Information
- Table 61: Y-mAbs Therapeutics Business Overview
- Table 62: Y-mAbs Therapeutics Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 63: Y-mAbs Therapeutics Therapeutic Radioligands Drug Product Portfolio
- Table 64: Y-mAbs Therapeutics Recent Developments
- Table 65: Telix Pharmaceuticals Company Information
- Table 66: Telix Pharmaceuticals Business Overview
- Table 67: Telix Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 68: Telix Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- Table 69: Telix Pharmaceuticals Recent Developments
- Table 70: RadioMedix Company Information
- Table 71: RadioMedix Business Overview
- Table 72: RadioMedix Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 73: RadioMedix Therapeutic Radioligands Drug Product Portfolio
- Table 74: RadioMedix Recent Developments
- Table 75: Philogen Company Information
- Table 76: Philogen Business Overview
- Table 77: Philogen Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 78: Philogen Therapeutic Radioligands Drug Product Portfolio
- Table 79: Philogen Recent Developments
- Table 80: Orano Med Company Information
- Table 81: Orano Med Business Overview
- Table 82: Orano Med Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 83: Orano Med Therapeutic Radioligands Drug Product Portfolio
- Table 84: Orano Med Recent Developments
- Table 85: Nordic Nanovector Company Information
- Table 86: Nordic Nanovector Business Overview
- Table 87: Nordic Nanovector Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 88: Nordic Nanovector Therapeutic Radioligands Drug Product Portfolio
- Table 89: Nordic Nanovector Recent Developments
- Table 90: Lantheus Company Information
- Table 91: Lantheus Business Overview
- Table 92: Lantheus Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 93: Lantheus Therapeutic Radioligands Drug Product Portfolio
- Table 94: Lantheus Recent Developments
- Table 95: Gilead Sciences Company Information
- Table 96: Gilead Sciences Business Overview
- Table 97: Gilead Sciences Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 98: Gilead Sciences Therapeutic Radioligands Drug Product Portfolio
- Table 99: Gilead Sciences Recent Developments
- Table 100: Fusion Pharmaceuticals Company Information
- Table 101: Fusion Pharmaceuticals Business Overview
- Table 102: Fusion Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 103: Fusion Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- Table 104: Fusion Pharmaceuticals Recent Developments
- Table 105: Curium Pharmaceuticals Company Information
- Table 106: Curium Pharmaceuticals Business Overview
- Table 107: Curium Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 108: Curium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- Table 109: Curium Pharmaceuticals Recent Developments
- Table 110: Curasight Company Information
- Table 111: Curasight Business Overview
- Table 112: Curasight Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 113: Curasight Therapeutic Radioligands Drug Product Portfolio
- Table 114: Curasight Recent Developments
- Table 115: Clarity Pharmaceuticals Company Information
- Table 116: Clarity Pharmaceuticals Business Overview
- Table 117: Clarity Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)

- Table 118: Clarity Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- Table 119: Clarity Pharmaceuticals Recent Developments
- Table 120: China Isotope & Radiation Company Information
- Table 121: China Isotope & Radiation Business Overview
- Table 122: China Isotope & Radiation Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 123: China Isotope & Radiation Therapeutic Radioligands Drug Product Portfolio
- Table 124: China Isotope & Radiation Recent Developments
- Table 125: Aurobindo Pharma Company Information
- Table 126: Aurobindo Pharma Business Overview
- Table 127: Aurobindo Pharma Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 128: Aurobindo Pharma Therapeutic Radioligands Drug Product Portfolio
- Table 129: Aurobindo Pharma Recent Developments
- Table 130: Actinium Pharmaceuticals Company Information
- Table 131: Actinium Pharmaceuticals Business Overview
- Table 132: Actinium Pharmaceuticals Revenue in Therapeutic Radioligands Drug Business (2021-2026) & (US\$ Million)
- Table 133: Actinium Pharmaceuticals Therapeutic Radioligands Drug Product Portfolio
- Table 134: Actinium Pharmaceuticals Recent Developments
- Table 135: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Therapeutic Radioligands Drug Product Image
- Figure 5: Global Therapeutic Radioligands Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Therapeutic Radioligands Drug Market Share by Type: 2025 VS 2032
- Figure 7: Beta-emitting Product
- Figure 8: Targeted Alpha Therapy Product
- Figure 9: Global Therapeutic Radioligands Drug Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 10: Global Therapeutic Radioligands Drug Market Share by Application: 2025 VS 2032
- Figure 11: Solid Tumor Product
- Figure 12: Non Hodgkin Lymphoma Product
- Figure 13: Global Therapeutic Radioligands Drug Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 14: Global Therapeutic Radioligands Drug Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 15: Global Therapeutic Radioligands Drug Market Share by Region: 2025 VS 2032
- Figure 16: Global Therapeutic Radioligands Drug Market Share by Players in 2025
- Figure 17: Global Therapeutic Radioligands Drug Manufacturers Established Date
- Figure 18: Global Top 5 and 10 Therapeutic Radioligands Drug Players Market Share by Revenue in 2025
- Figure 19: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 20: North America Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 21: North America Therapeutic Radioligands Drug Market Share by Country (2021-2032)
- Figure 22: United States Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 23: Canada Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 24: Mexico Therapeutic Radioligands Drug Market Share by Country (2021-2032)
- Figure 25: Europe Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Europe Therapeutic Radioligands Drug Market Share by Country (2021-2032)
- Figure 27: Germany Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 28: France Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: U.K. Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: Italy Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: Spain Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Russia Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Netherlands Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Nordic Countries Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Asia-Pacific Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Asia-Pacific Therapeutic Radioligands Drug Market Share by Country (2021-2032)
- Figure 37: China Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Japan Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: South Korea Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: India Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: India Therapeutic Radioligands Drug Market Share by Country (2021-2032)
- Figure 42: Australia Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: China Taiwan Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)

- Figure 44: Southeast Asia Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: South America Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: South America Therapeutic Radioligands Drug Market Share by Country (2021-2032)
- Figure 47: Brazil Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: Argentina Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: Chile Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: Colombia Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Peru Therapeutic Radioligands Drug Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Novartis Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 53: Mundipharma Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 54: Bayer Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 55: Y-mAbs Therapeutics Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 56: Telix Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 57: RadioMedix Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 58: Philogen Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 59: Orano Med Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 60: Nordic Nanovector Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 61: Lantheus Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 62: Gilead Sciences Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 63: Fusion Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 64: Curium Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 65: Curasight Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 66: Clarity Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 67: China Isotope & Radiation Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 68: Aurobindo Pharma Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)
- Figure 69: Actinium Pharmaceuticals Revenue Growth Rate in Therapeutic Radioligands Drug Business (2021-2026)